Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vivos Therapeutics (VVOS) Other Non Operating Income (2021 - 2025)

Historic Other Non Operating Income for Vivos Therapeutics (VVOS) over the last 5 years, with Q3 2025 value amounting to -$679000.0.

  • Vivos Therapeutics' Other Non Operating Income fell 367222.22% to -$679000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$914000.0, marking a year-over-year decrease of 156181.82%. This contributed to the annual value of -$110000.0 for FY2024, which is 4811.32% up from last year.
  • According to the latest figures from Q3 2025, Vivos Therapeutics' Other Non Operating Income is -$679000.0, which was down 367222.22% from -$163000.0 recorded in Q2 2025.
  • Vivos Therapeutics' Other Non Operating Income's 5-year high stood at $59000.0 during Q3 2021, with a 5-year trough of -$679000.0 in Q3 2025.
  • For the 5-year period, Vivos Therapeutics' Other Non Operating Income averaged around -$71263.2, with its median value being -$36000.0 (2022).
  • Its Other Non Operating Income has fluctuated over the past 5 years, first surged by 23421.05% in 2023, then crashed by 367222.22% in 2025.
  • Quarter analysis of 5 years shows Vivos Therapeutics' Other Non Operating Income stood at -$95000.0 in 2021, then skyrocketed by 60.0% to -$38000.0 in 2022, then skyrocketed by 63.16% to -$14000.0 in 2023, then tumbled by 385.71% to -$68000.0 in 2024, then plummeted by 898.53% to -$679000.0 in 2025.
  • Its Other Non Operating Income was -$679000.0 in Q3 2025, compared to -$163000.0 in Q2 2025 and -$4000.0 in Q1 2025.